Clik here to view.
ZAI Lab and Hanmi Execute a License Agreement to Develop Novel EGFR Targeted...
SHANGHAI & SEOUL, South Korea ZAI Lab Limited and Hanmi Pharmaceutical Co., Ltd. (Hanmi)(KRX: 128940) announced today that they have executed a collaboration and license agreement under which...
View ArticleClik here to view.
Hitachi Medical Announces Release of New Evolution 5 MRI Software Platform
CLEVELAND In conjunction with the upcoming RSNA 2015 exhibition, Hitachi Medical Systems America, Inc. (HMSA) announced the availability of their new MRI software platform “Evolution 5” available...
View ArticleClik here to view.
新调研显示，森永的BB536益生菌奶具有胃肠道健康和抗衰老效益
东京 (美国商业资讯) — 日本领先的乳品公司森永乳业株式会社（东京：2264）今天揭晓了一项全国性调研的结果，该调研与日本东京医疗保健大学联合开展，探讨超过20,000 名中年至老年男女的健康状况，旨在调查定期消费含长双歧杆菌BB536 的高钙奶与健康状况之间的关系。 Smart News Releases（智能新闻稿）是一个多媒体平台。在此处查看完整新闻稿：...
View ArticleClik here to view.
美国FDA核准武田首个也是唯一的口服蛋白酶体抑制剂NINLARO® (ixazomib)用于治疗多发性骨髓瘤
Smart Multimedia Gallery ビデオタイトル QuickTimeで再生 WindowsMediaで再生 马萨诸塞州剑桥和日本大阪 (美国商业资讯)–武田药品工业株式会社(TSE: 4502)今天宣布，美国食品药品管理局(FDA)已核准首个且唯一的口服蛋白酶体抑制剂NINLARO®...
View ArticleClik here to view.
Solasia and Lee’s Pharma Announce License, Promotion and Supply Agreement...
TOKYO & HONG KONG Solasia Pharma K.K. (Headquarters: Tokyo, Japan, President: Yoshihiro Arai, hereinafter “Solasia”) and Lee’s Pharmaceutical Holdings Limited (hereinafter “Lee’s Pharma”)(SEHK...
View ArticleClik here to view.
多発性骨髄腫を治療するための経口プロテアソーム阻害薬として初にして唯一の武田薬品のNINLARO®（イキサゾミブ）を米FDAが承認
Smart Multimedia Gallery ビデオタイトル QuickTimeで再生 WindowsMediaで再生 米マサチューセッツ州ケンブリッジ & 大阪 （ビジネスワイヤ） — 武田薬品工業株式会社（TSE:...
View ArticleClik here to view.
Olea Medicalが国際コンテスト「Olea Innovators」を開始
仏ラ・シオタ （ビジネスワイヤ） — 2015年11月30日 MRI／CT画像用の最先端の高度なポストプロセッシング／可視化ソリューションOlea Sphere™を設計したOlea Medical™は、初開催となる「Olea Innovators」コンテストの開始を発表しました。 「Olea...
View ArticleClik here to view.
Chugai Pharma Marketing Changed Its Corporate Name to Chugai Pharma Europe
TOKYO Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced today that Chugai Pharma Marketing Ltd., a wholly-owned subsidiary of Chugai located in London, changed its corporate name to Chugai...
View ArticleClik here to view.
bluebird bio and ViroMed Enter into License Agreement for Novel Antibodies to...
CAMBRIDGE, Mass. & SEOUL, Korea bluebird bio, Inc. (Nasdaq: BLUE) and ViroMed Co., Ltd. today announced that they have entered into an exclusive license agreement to research, develop and...
View ArticleClik here to view.
Nohla Therapeutics Launches with Major US Cancer Research Institute Deal,...
SEATTLE Nohla Therapeutics Inc. (Nohla), a new cellular therapies start-up based in Seattle, Washington, is pleased to announce the signing of an exclusive licensing and collaboration agreement with...
View ArticleClik here to view.
Samsung Bioepis’ RENFLEXIS® Infliximab Biosimilar Receives Regulatory...
INCHEON, Korea Samsung Bioepis Co., Ltd. today announced that Korea’s Ministry of Food and Drug Safety (MFDS) has approved RENFLEXIS® – a biosimilar version of Remicade® (infliximab), also known as...
View ArticleClik here to view.
Promega NanoBiT Complementation Assay Named a Top 10 Innovation
Smart Multimedia Gallery ビデオタイトル QuickTimeで再生 WindowsMediaで再生 MADISON, Wis. The Scientist named Promega NanoBiT™ (NanoLuc® Binary Technology) Assay as a Top 10 Innovation for 2015. This is the third...
View ArticleClik here to view.
Clik here to view.
武田报告ADCETRIS® (Brentuximab Vedotin)的5年总生存数据，结果显示复发/难治霍奇金淋巴瘤可持久缓解
佛罗里达州奥兰多 (美国商业资讯) — 武田药品工业株式会社(TSE:4502)发布了 brentuximab vedotin单药治疗自体干细胞移植(ASCT)后复发或难治霍奇金淋巴瘤枢纽性2期研究的治疗后随访数据。数据显示，ADCETRIS治疗患者的5年总生存(OS)率估值为41% (95% CI: 31%, 51%)；中位OS期为40.5个月（95% CI: 28.7, 61.9...
View ArticleClik here to view.
武田が多発性骨髄腫の治療のために最近承認された週1回経口プロテアソーム阻害薬として初にして唯一のNINLARO®（イキサゾミブ）の第3相TOURMALIN...
米フロリダ州オーランド （ビジネスワイヤ） —...
View ArticleClik here to view.
武田呈报近期核准用于多发性骨髓瘤的首个也是唯一的每周一次口服蛋白酶体抑制剂NINLARO® (ixazomib)的3期TOURMALINE-MM1研究数据
佛罗里达州奥兰多 (美国商业资讯) — 武田药品工业株式会社(TSE:4502)今天在美国血液学会(ASH)第57届年会和展览上发布了TOURMALINE-MM1试验的结果，该结果显示，NINLARO®...
View ArticleClik here to view.
武田薬品、アドセトリス（ブレンツキシマブ・ベドチン）の5年全生存率データが再発性／難治性ホジキンリンパ腫患者で長期寛解を示すと報告
米フロリダ州オーランド （ビジネスワイヤ） — 武田薬品工業株式会社（TSE:4502）は、自家幹細胞移植（ASCT)後の再発性／難治性ホジキンリンパ腫の治療を目的としたブレンツキシマブ・ベドチン単剤療法のピボタル第2相試験から得られた治療後フォローアップのデータを発表しました。データは、アドセトリスによる治療を受けた患者の推定5年全生存率（OS）が41パーセント（95% CI:...
View ArticleClik here to view.
Bellicum and Astellas Announce License Agreement for Cancer Target PSCA in...
HOUSTON & TOKYO Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM, “Bellicum”) and Astellas Pharma Inc. (TSE: 4503, “Astellas”) today announced that Agensys, Inc. (“Agensys”), an affiliate of...
View ArticleClik here to view.
NINLARO® (ixazomib) Now Available for Patients
CAMBRIDGE, Mass. & OSAKA, Japan NINLARO® (ixazomib) capsules, the first and only oral proteasome inhibitor, are now available in the United States. NINLARO is indicated in combination with...
View ArticleClik here to view.
Chugai’s ALK Inhibitor “Alecensa®” Accelerated Approval in Three Months after...
TOKYO Chugai Pharmaceutical Co., Ltd. (TOKYO:4519) announced today that Genentech Inc., a member of the Roche Group, obtained approval from the U.S. Food and Drug Administration (FDA), for the...
View Article